Multicentered clinical evaluation of cefoperazone for the treatment of lower respiratory tract infections.
Adult patients with bacterial infections of the lower respiratory tract were given either cefoperazone or cefamandole in a multicenter clinical study of the clinical and bacteriologic efficacy of cefoperazone. Clinical diagnoses included pneumonia, bronchitis, lung abscess, and bronchiectasis. Efficacy was evaluated in 119 patients given cefoperazone and 73 patients given cefamandole. Major pathogens isolated included Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Satisfactory clinical responses were noted for 96% of the patients in both treatment groups, including 14 of 17 patients given cefoperazone who were primarily infected with P. aeruginosa. Satisfactory bacteriologic responses were noted for 88% of the group given cefoperazone and 89% of the group given cefamandole. Adverse reactions related to the antibiotic occurred infrequently in each treatment group. The results of this study indicate that cefoperazone is a safe and effective antibiotic for the treatment of lower respiratory tract infections due to S. pneumoniae, H. influenzae, S. aureus, and many gram-negative bacilli, including susceptible strains of P. aeruginosa, in adult patients.